Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) CFO Jamie Samath sold 269 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the completion of the sale, the chief financial officer now owns 3,282 shares of the company’s stock, valued at $1,936,380. This represents a 7.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Jamie Samath also recently made the following trade(s):
- On Wednesday, January 29th, Jamie Samath sold 94 shares of Intuitive Surgical stock. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34.
- On Tuesday, December 10th, Jamie Samath sold 270 shares of Intuitive Surgical stock. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50.
- On Friday, November 29th, Jamie Samath sold 188 shares of Intuitive Surgical stock. The stock was sold at an average price of $539.00, for a total value of $101,332.00.
- On Tuesday, November 26th, Jamie Samath sold 108 shares of Intuitive Surgical stock. The shares were sold at an average price of $542.06, for a total value of $58,542.48.
Intuitive Surgical Trading Up 2.2 %
Shares of Intuitive Surgical stock opened at $595.70 on Tuesday. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The firm’s 50-day moving average price is $554.85 and its two-hundred day moving average price is $514.80. The stock has a market capitalization of $212.18 billion, a price-to-earnings ratio of 92.93, a P/E/G ratio of 5.67 and a beta of 1.39.
Institutional Investors Weigh In On Intuitive Surgical
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on ISRG shares. Citigroup raised their price objective on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Barclays raised their price target on shares of Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. BTIG Research upped their price objective on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. UBS Group lifted their target price on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $613.10.
Read Our Latest Analysis on Intuitive Surgical
About Intuitive Surgical
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Read More
- Five stocks we like better than Intuitive Surgical
- Compound Interest and Why It Matters When Investing
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What is a Dividend King?
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.